118 related articles for article (PubMed ID: 26048126)
1. [Not Available].
Stingl W
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():55. PubMed ID: 26048126
[No Abstract] [Full Text] [Related]
2. Therapy for hepatitis C genotype 3: moving forward.
Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Wolf E; Rüsenberg R
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():42-5. PubMed ID: 26048120
[No Abstract] [Full Text] [Related]
4. [In HIV-HCV co-infection check for drug interactions].
Neumaier J
MMW Fortschr Med; 2016 Jun; 158 Suppl 1():62. PubMed ID: 27259910
[No Abstract] [Full Text] [Related]
5. MSF pushes down price of generic hepatitis C drugs to new low level.
Wise J
BMJ; 2017 Nov; 359():j5054. PubMed ID: 29092825
[No Abstract] [Full Text] [Related]
6. Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV.
Ackens R; Posthouwer D
Haemophilia; 2016 May; 22(3):e223-5. PubMed ID: 26988201
[No Abstract] [Full Text] [Related]
7. Sofosbuvir and daclatasvir.
Hessel MH; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2016 Sep; 82(3):878-9. PubMed ID: 27198488
[No Abstract] [Full Text] [Related]
8. Sofosbuvir Causing Diabetes Mellitus: Is there a Link?
Jabeen S; Rashid O; Furqan S
J Coll Physicians Surg Pak; 2018 May; 28(5):414. PubMed ID: 29690979
[No Abstract] [Full Text] [Related]
9. Screening and Treatment Program to Eliminate Hepatitis C in Egypt.
Waked I; Esmat G; Elsharkawy A; El-Serafy M; Abdel-Razek W; Ghalab R; Elshishiney G; Salah A; Abdel Megid S; Kabil K; El-Sayed MH; Dabbous H; El Shazly Y; Abo Sliman M; Abou Hashem K; Abdel Gawad S; El Nahas N; El Sobky A; El Sonbaty S; El Tabakh H; Emad E; Gemeah H; Hashem A; Hassany M; Hefnawy N; Hemida AN; Khadary A; Labib K; Mahmoud F; Mamoun S; Marei T; Mekky S; Meshref A; Othman A; Ragab O; Ramadan E; Rehan A; Saad T; Saeed R; Sharshar M; Shawky H; Shawky M; Shehata W; Soror H; Taha M; Talha M; Tealaab A; Zein M; Hashish A; Cordie A; Omar Y; Kamal E; Ammar I; AbdAlla M; El Akel W; Doss W; Zaid H
N Engl J Med; 2020 Mar; 382(12):1166-1174. PubMed ID: 32187475
[No Abstract] [Full Text] [Related]
10. Indian hepatitis C drug patent decision shakes public health community.
't Hoen EFM
Lancet; 2016 Jun; 387(10035):2272-2273. PubMed ID: 27238944
[No Abstract] [Full Text] [Related]
11. [Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].
Mar J; Mar-Barrutia L; Gimeno-Ballester V; San Miguel R
Med Clin (Barc); 2016 Jan; 146(2):61-4. PubMed ID: 26654558
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.
McEwan P; Bennett H; Ward T; Webster S; Gordon J; Kalsekar A; Yuan Y; Brenner M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):173-80. PubMed ID: 26545086
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir.
Chia XX; Cherepanoff S; Danta M; Furlong T
Nephrology (Carlton); 2018 Apr; 23(4):379-380. PubMed ID: 29520905
[No Abstract] [Full Text] [Related]
15. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
16. HIV/HCV Co-infection: Overcoming Barriers to Treatment.
Gross C; Akoth E; Price A; Kattakuzhy S; Silk R; Rosenthal E
J Assoc Nurses AIDS Care; 2016; 27(4):524-9. PubMed ID: 26996983
[TBL] [Abstract][Full Text] [Related]
17. [Sofosbuvir (Sovaldi), oral administration].
Duh D; Van Genechten D
J Pharm Belg; 2015 Mar; (1):61-3. PubMed ID: 26571798
[No Abstract] [Full Text] [Related]
18. Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
Stern R; Hametner S; Ramona AZ; Moser S; Karpi A; Laferl H; Stauber RE; Zoller HM; Maieron A; Vogel W; Graziadei I; Gschwantler M; Kozbial K; Freissmuth C; Hofer H; Ferenci P
Am J Gastroenterol; 2016 May; 111(5):744-5. PubMed ID: 27151123
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
